| Thank you to our sponsors. |
|
|
Founded in 2004, BioStrategy Partners is a virtual incubator providing technology and business development services to emerging-stage life sciences companies and university-based research projects in the Greater Philadelphia region. BioSP specializes in offering business guidance and support to first-time entrepreneurs, scientific founders, and university-based principal investigators. For more information, please visit our web site, http://www.biostrategypartners.org.
| |
|
From the Executive Director
Karen J. Hanson, Ph.D. |
|
I am pleased to welcome Travelers as a Bronze Level Sponsor of BioStrategy Partners! Travelers offers property and liability coverage for the medical device and biotechnology industries as well as a broad range of insurance and risk management solutions for all sizes of technology industry companies. Jessica Landau, Medical Technology Underwriter, is located in the Blue Bell office.
In the February 2009 BioNewslink, we featured an article on our Commercialization Germinator by Maureen O'Leary, BioSP's Program Director. This month, BioSP Portfolio Manager Lorraine Keller writes about our Diligence and Corporate Development Programs. There is a common theme-the very beginning of the development continuum! All of our programs are designed to educate and incubate pre-seed life sciences companies and university-based technologies with commercial potential. Please visit our web site, www.biostrategypartners.org to learn more. |
| Practical Knowledge Series:
Upcoming Programs |
|
Thursday, May 14, 2009
8:30AM - 11:00AM
Clinical Trials: Managing Expectations While Managing Budgets
Presented by Fox Rothschild LLP
Breakfast Sponsor: Bridgepoint Insurance Group
Lankenau Institute for Medical Research
The Walter and Lenore Annenberg Conference Center
Annenberg Room 101A
190 Lancaster Avenue
Wynnewood, PA 1909 |
| LIMR Accelerating New Nanotherapy Platform with Help of National Cancer Institute |
|
 LIMR Professor, Dr. Janet Sawicki and her collaborators at the Massachusetts Institute of Technology (MIT), have been selected by the National Cancer Institute (NCI) for a research collaboration to perform preclinical studies on their novel nanotherapy for the treatment of solid tumors. The research will be conducted by the NCI's Nanotechnology Characterization Laboratory (NCL), part of a major program, the Alliance for Nanotechnology in Cancer, to advance the medical applications of nanotechnology. The initial NCL efforts will focus on the characterization of this new product for its adsorption, distribution, and toxicity properties in both in vitro and in vivo studies. The intent of these studies is to produce data so that the therapy can advance to clinical trials. In early stage laboratory studies, this technology has been applied to treatment of prostate, ovarian, pancreatic, and cervical cancer models. |
| BioStrategy Partners Delivers Dynamic, Hands-on Assistance to Life Sciences Entrepreneurs
By: Lorraine Keller, Ph.D. , Portfolio Manager |
|
|
I have been a member of BioStrategy Partners since its founding in 2004. As an entrepreneur and co-founder of three start-up biotechnology companies, I have been able to bring a first-person perspective on the challenges of establishing and growing new businesses based on high-risk, high value technologies.
I like to think of BioStrategy Partners as a 'virtual incubator with a difference' because we are one of the few organizations that work with companies at their earliest stages, often when they are only a concept in the mind of the entrepreneur with little or no business analysis in place.
We designed the Corporate Development Program as a dynamic, hands-on, customized service model to educate entrepreneurs. We assist our clients with defining and achieving their highest priority business goals. The foundation and starting point of our service process is the diligence review- and this is where BioSP is different- unlike investor diligence, where the objective is to evaluate whether a company is a good investment risk, our goal is to determine how we can help each company to set and meet important milestones, typically directed to preparation for early angel funding, seed investment, or seeking a corporate partnership.
As Portfolio Manager, I participate in all of the diligence sessions and work closely with companies invited into the Corporate Development Program. My job includes a lot of mentoring, and I have always found it very rewarding to be part of an organization that helps early-stage entrepreneurs learn how to successfully grow their life sciences businesses.
|
| News From Our Community |
|
Charlie Huntington of THE HUNTINGTON/KRAUS FINANCIAL GROUP has relocated with his team to Wells Fargo/Wachovia Securities, LLC in Berwyn, Pennsylvania. In addition, he has been elected to the Board of Directors of The Philadelphia Human Resource Planning Society. Charlie can be reached at charles.huntingtonjr@wachoviasec.com.
Predictive Inc., a KIZ Pipeline company and a telehealth monitoring company engaged in early detection of infections, has announced the hiring of James F. Richter as President and CEO. Prior to joining Predictive, Jamie served as Commercial Vice President for SymCare Personalized Health Solutions, a Johnson & Johnson operating company.
John Beiswenger, Co-Founder and Chairman of Predictive, commented, "This event represents a major milestone in the evolution of Predictive Inc. Jamie, through his 20-year career in health care, brings to the company a deep understanding of chronic care management, hybrid device/service business models, and related payor and reimbursement opportunities. Our progress in building a strong senior management team represents the final building block necessary to embark on a fundraising campaign."
Prescient Medical, a KIZ company, is pleased to announce that CESLIE - The Women's Network will co-host a Momentum Women™ award event honoring Patricia Scheller, Chief Executive Officer of Prescient Medical, for her success in business, contribution to advances in healthcare,and dedication to the prevention and treatment of cardiovascular disease. Alexandra J. Lansky, MD,Roxana Mehran, MD, Jutta Sayles, Cynthia Ekberg Tsai, Jennifer K. Zimmons, Ph.D., and editor-in-chief Ceslie Armstrong will host the cocktail soiree and networking event with members of Momentum Women™, a distinguished group of business leaders, at The World Bar, 845 United Nations Plaza in New York City on Tuesday, March 31, 2009 from 6:00 - 8:00 p.m.
For pre-event information and media registration, please contact Quinn Fisher, qfisher@ceslie.com at (212)217-9079 (or Jennifer K. Zimmons, Ph.D., jzimmons@sgi-ir.com).
Inteprod LLC, an innovative and highly experienced full-service supplier of comprehensive design, development, and contract manufacturing solutions for products in the medical device, medical diagnostics, and food safety diagnostics industries, is pleased to announce the addition of Daniel A. Miller to Inteprod's team. Daniel joins Inteprod as Vice President of Engineering and will be responsible for all engineering activities including project management, product development, and client support.
Daniel brings significant Engineering, R & D, and Operations expertise, and more than 30 years of proven experience and success in strategic innovation and leadership within the medical and food safety industries. Prior to joining Inteprod, Daniel held senior level positions with Integra Lifesciences Corporation and the Campbell Soup Company. | |
|
